Scope and Claims for US Patent 5,476,875 (Method of Treating Parkinsonism with L-Dopa + Peripheral Decarboxylase Inhibitor + Benzophenone Derivative)
US 5,476,875 is a US method-of-use patent built around a three-part therapeutic composition: (i) L-dopa, (ii) a peripheral decarboxylase inhibitor, and (iii) a specific benzophenone derivative defined by a structural formula with Ra and Rb ring substitutions and a hydrolyzable ester/ether option at Rc. The claims are drafted as methods of treating parkinsonism/Parkinson’s disease by administering the claimed composition. Claim 2–4 and 6–8 lock in specific substituted benzophenones, while claim 1 and claim 5 preserve broader formula coverage.
What does US 5,476,875 claim cover: scope of the “compound of the formula” and allowable substitutions?
Core claim scaffold (claims 1 and 5). The patent covers administering an effective amount of a pharmaceutical composition comprising:
- L-dopa
- a peripheral decarboxylic (decarboxylase) inhibitor
- a compound of the formula (structural depiction in the claim text) with variable substituents:
- Ra is nitro or cyano
- Rb is hydrogen or halogen
- Rc is –CO–R1, where R1 is:
- a phenyl group optionally mono- or disubstituted by halogen, cyano, hydroxy, or lower alkyl, or
- an ester or ether derivative of that phenyl group hydrolyzable under physiological conditions
- plus a therapeutically inert carrier material and “pharmaceutically acceptable salt thereof” where applicable.
How the formula language narrows vs broadens
- Ra constraint is tight: only nitro or cyano. That excludes other electron-withdrawing groups (e.g., trifluoromethyl) unless they fit the definition through literal nitro/cyano.
- Rb constraint is moderate: only H or halogen (no alkyl, no hydroxy, no additional nitro/cyano beyond Ra).
- Rc defines a benzophenone core with a phenyl substituent handle: Rc is a carbonyl linker to R1. R1 is a substituted phenyl or a hydrolyzable ester/ether derivative of that phenyl substituent.
- Hydrolyzable prodrug concept is embedded: the claim permits ester/ether derivatives that convert under physiological conditions to the phenolic/phenyl form, so literal coverage extends to certain masked forms if they hydrolyze as described.
Substitution patterns explicitly permitted at R1
R1 can be:
- phenyl with optional mono- or disubstitution by:
- halogen
- cyano
- hydroxy
- lower alkyl
- or the ester/ether derivative of such a phenyl group that is hydrolyzable under physiological conditions.
That means the patent’s “compound of the formula” category is not limited to a single benzophenone. It sweeps across multiple substituted benzophenones and potentially prodrug-like ester/ether variants at Rc.
Which specific benzophenones are expressly claimed (dependent claims 2–4 and 6–8)?
The patent expressly recites three benzophenone compounds in the dependent claims, tying them to specific parkinsonism/Parkinson’s disease method treatment.
Claim 2 (depending on claim 1):
- 3,4-dihydroxy-5-nitrobenzophenone
Claim 3 (depending on claim 1):
- 2’-fluoro-3,4-dihydroxy-5-nitrobenzophenone
Claim 4 (depending on claim 1):
- 3,4-dihydroxy-4’-methyl-5-nitrobenzophenone
Claim 6 (depending on claim 5):
- 3,4-dihydroxy-4’-methyl-5-nitrobenzophenone
Claim 7 (depending on claim 6):
- 3,4-dihydroxy-5-nitrobenzophenone
Claim 8 (depending on claim 6):
- 2’-fluoro-3,4-dihydroxy-5-nitrobenzophenone
What this means for infringement scope.
- Literal coverage is clearest for these three specific molecules, since the dependent claims anchor to them by name.
- If a third-party uses a different benzophenone within the claim formula range (Ra nitro/cyano, Rb H/halogen, Rc carbonyl to substituted phenyl or hydrolyzable ester/ether), they still fall within the broader independent claims provided the exact structural requirements are met.
What is the functional structure of claim coverage: is it a “composition patent” or a method-of-use administration claim?
This is drafted as a method claim:
- The preamble and body state “A method of treating parkinsonism … administering … an effective amount of a pharmaceutical composition comprising …”.
- Even though it recites composition elements, the infringement trigger is the act of administering the specified composition to a host needing treatment.
Practical implication for enforcement.
- For licensing or litigation strategy, it is typically more straightforward to pursue entities performing or directing the administration/use (clinicians, branded commercialization in many frameworks, or perhaps manufacturers tied to labeled instructions), while generic manufacturers often face different exposure depending on whether they supply a label that instructs the claimed combination.
Inside each claim, the three elements are conjunctive.
- L-dopa is required.
- A peripheral decarboxylase inhibitor is required.
- The benzophenone derivative is required.
- The carrier is required but limited to “therapeutically inert carrier material.”
So partial substitution (e.g., replacing the benzophenone with a different adjunct) is outside literal scope.
How broad is the “peripheral decarboxylic inhibitor” component in these claims?
The claims do not specify a named inhibitor in the text you provided. They only require:
- “a peripheral decarboxylic inhibitor” / “peripheral decarboxylase inhibitor.”
Claim scope consequences:
- Any compound meeting the ordinary meaning of “peripheral decarboxylase inhibitor” could fall, including multiple known class members historically used with L-dopa in Parkinson’s therapy.
- Because the claims do not list specific molecules, this element is likely less constraining than the benzophenone formula.
Business takeaway for freedom-to-operate (FTO).
- If the bottleneck compound is the benzophenone derivative, the inhibitor element becomes a variable that likely expands potential infringement risk across the market if the benzophenone is used with any peripheral decarboxylase inhibitor.
What therapeutic indications are covered: “parkinsonism” vs “Parkinson’s disease” do these claims differ?
Claims 1–4 use “parkinsonism” and claim 5–8 use “Parkinson’s disease”. Claim 1 and claim 5 have the same functional structure, but the dependent claim numbering and minor wording differences appear in your excerpt.
Practical effect:
- Both cover the same clinical space: treatments for patients with parkinsonism/Parkinson’s disease.
- The broader legal question becomes whether a challenger could argue the patent intended one condition and not the other. On the face of the claim language, they are treated as overlapping categories.
How strong is the claim’s structural limit: does the benzophenone formula create clear design-around space?
Yes, the benzophenone definition creates the most identifiable design-around lever because it is detailed:
- Ra must be nitro or cyano.
- Rb must be H or halogen.
- Rc must be –CO–R1 where R1 is a substituted phenyl or hydrolyzable ester/ether derivative thereof.
Likely design-around approaches (conceptually, based on claim structure):
- Replace Ra with a substituent outside nitro/cyano.
- Replace the benzophenone carbonyl linkage pattern that defines Rc.
- Use an R1 substituent that is not a phenyl or not substituted in the permitted ways (or not a hydrolyzable ester/ether derivative).
Because the dependent claims are named to specific nitrobenzophenones, those are the easiest targets for literal infringement. Avoidance would focus on staying outside the Ra/Rb/Rc structural envelope.
What formulations are protected: does the patent cover prodrugs and pharmaceutically acceptable salts?
The claim language explicitly includes:
- “a compound of the formula … or a pharmaceutically acceptable salt thereof”
- and ester/ether derivatives “hydrolyzable under physiological conditions.”
That covers at least two practical categories:
- Active benzophenone derivatives meeting the formula.
- Hydrolyzable ester/ether masked derivatives that release the active form in vivo.
The claims do not limit to any specific dosage form (tablet, capsule, etc.), only to administration of an “effective amount” in a pharmaceutical composition with an inert carrier.
Which combination therapies are within the patent if a third-party uses L-dopa + decarboxylase inhibitor + another adjunct?
Under strict claim construction logic from the provided text:
- Only combinations that include the required benzophenone derivative (formula-defined or named species) are covered.
- Alternative adjuncts (different chemical entities) are not covered unless they fall within the benzophenone definition.
So the patent is best read as an adjunct-specific method claim where L-dopa plus decarboxylase inhibitor is necessary but not sufficient.
How many distinct “compound targets” are in the claims?
Based on your excerpt:
Independent claim compound class
- All compounds matching the formula with:
- Ra = nitro or cyano
- Rb = H or halogen
- Rc = –CO–R1
- R1 = substituted phenyl (mono- or disubstituted) by halogen/cyano/hydroxy/lower alkyl
- or hydrolyzable ester/ether derivatives of that phenyl.
Dependent claim species (explicit)
- 3,4-dihydroxy-5-nitrobenzophenone
- 2’-fluoro-3,4-dihydroxy-5-nitrobenzophenone
- 3,4-dihydroxy-4’-methyl-5-nitrobenzophenone
Total explicitly named benzophenone species in the provided claims: 3.
Patent landscape positioning: what can be inferred about likely competitive exposure without the rest of the record?
From the claim text alone, you can infer the competitive pressure points:
- The patent’s unique value is the benzophenone adjunct scaffold used with standard L-dopa + peripheral decarboxylase inhibitor therapy.
- Competitive risk concentrates on programs that:
- develop L-dopa combo regimens with benzophenone nitro/cyano derivatives matching the structure, or
- develop hydrolyzable ester/ether prodrugs of such benzophenones.
However, a complete “landscape” with:
- expiration dates,
- other US continuations/divisionals,
- related family members,
- prosecution history,
- litigation,
- Orange Book status,
- FDA approvals,
cannot be produced from the excerpt provided and would require the patent document and external registries.
Given the constraints, this analysis stays confined to scope and claims.
Key Takeaways
- US 5,476,875 claims administration methods for parkinsonism/Parkinson’s disease requiring a three-component therapeutic composition: L-dopa + a peripheral decarboxylase inhibitor + a benzophenone derivative defined by a tight structural formula.
- The most constraining element is the benzophenone:
- Ra is restricted to nitro or cyano,
- Rb is H or halogen,
- Rc is –CO–R1, where R1 is a substituted phenyl or a hydrolyzable ester/ether derivative of that phenyl.
- Dependent claims expressly cover three specific nitrobenzophenones:
3,4-dihydroxy-5-nitrobenzophenone, 2’-fluoro-3,4-dihydroxy-5-nitrobenzophenone, and 3,4-dihydroxy-4’-methyl-5-nitrobenzophenone.
- The claim language supports coverage of pharmaceutically acceptable salts and prodrug-like hydrolyzable ester/ether forms of the defined benzophenone scaffold.
- Design-around is most feasible by staying outside the benzophenone formula envelope rather than by swapping the L-dopa/decarboxylase inhibitor backbone.
FAQs
1) Does US 5,476,875 cover L-dopa plus a peripheral decarboxylase inhibitor without the benzophenone?
No. The claims are conjunctive and require administration of a composition that includes the specified benzophenone derivative.
2) Can a competitor be outside the patent by changing Ra from nitro/cyano to another electron-withdrawing group?
Yes in principle, because Ra is limited to nitro or cyano by the claim formula.
3) Are ester or ether derivatives covered if they hydrolyze in the body?
Yes. The claim explicitly permits ester or ether derivatives of the phenyl group at Rc that are hydrolyzable under physiological conditions.
4) What are the three explicitly named compound embodiments in the dependent claims?
3,4-dihydroxy-5-nitrobenzophenone; 2’-fluoro-3,4-dihydroxy-5-nitrobenzophenone; 3,4-dihydroxy-4’-methyl-5-nitrobenzophenone.
5) Is the claim limited to Parkinson’s disease only, or does it also cover parkinsonism?
It covers both terms across different claims: parkinsonism (claims 1–4) and Parkinson’s disease (claims 5–8) using the same underlying administration concept.
References
No external sources were cited because the provided prompt did not include the full patent specification (e.g., drawings, description, claim numbering beyond the excerpt) or any bibliographic metadata needed to verify and cite additional records.
